Under siege hip-maker Smith & Nephew loses its boss
Smith & Nephew sprung a surprise on its investors with the departure of its chief executive after four years at the helm.
David Illingworth is jumping ship as the medical equipment and artificial hip-maker remains under siege by larger rivals looking to swallow up the Footsie stalwart.
Standing down had been a 'very personal and difficult decision', said the 57-year-old, who plans to return to the US after leaving S&N in August.
Suitors: It is understood that Johnson & Johnson and rival Biomet have recently made informal approaches to S&N
He told the Mail: 'Investors have been very gracious. It's been quite overwhelming.' His replacement is Olivier Bohuon, 52, who has had spells at GlaxoSmithKline and US giant Abbott Laboratories.
Given the welter of predators circling the British firm, investors will hope that Bohuon lasts longer at S&N than he did at his last job.
He was hired to run French drugs firm Pierre Fabre in September, but quit less than five months later after reports of a 'profound' falling-out with the group's founder.
But according to Illingworth, Bohuon had been in talks with S&N for 'quite a while', suggesting the Frenchman was prised away. The first item on Bohuon's agenda could be to fend away the raft of unwanted suitors set to be eyeing up S&N. It is understood that US healthcare giant Johnson & Johnson and rival Biomet have recently made informal approaches.
Illingworth remained tight-lipped on the takeover speculation. Last month S&N insisted it was 'not engaged in any discussions which could lead to a merger or a takeover'.
Still, S&N is regarded as vulnerable. Analysts believe that a takeover of the British firm could unleash a long-awaited wave of consolidation across the industry.
Illingworth's final set of annual results marked the end of a three-year programme to improve earnings. Trading profits rose 9 per cent to £173million during the final three months of 2010 on revenues of £683million.
Illingworth struck a confident note on S&N's prospects this year despite the 'well understood challenges' facing the industry.
Governments are looking to share the pain of austerity among their main private sector suppliers, including healthcare firms such as S&N (up 15p to 727p).
Drugs group Shire (up 15p to 1671p) expects revenues to jump 16 per cent this year as its rare disease wing continues to benefit from the disarray engulfing a key US rival. Shire reported a 4 per cent rise in turnover to £580million between October and December.
Most watched Money videos
- BMW's Vision Neue Klasse X unveils its sports activity vehicle future
- Will the high-flying US stock market stumble if rate cuts don't arrive?
- How to invest for income and growth: SAINTS' James Dow
- MailOnline asks Lexie Limitless 5 quick fire EV road trip questions
- 'Now even better': Nissan Qashqai gets a facelift for 2024 version
- Tesla unveils new Model 3 Performance - it's the fastest ever!
- Skoda reveals Skoda Epiq as part of an all-electric car portfolio
- 2025 Aston Martin DBX707: More luxury but comes with a higher price
- Land Rover unveil newest all-electric Range Rover SUV
- Blue Whale fund manager on the best of the Magnificent 7
- Mini Cooper SE: The British icon gets an all-electric makeover
- Mini celebrates the release of brand new all-electric car Mini Aceman
- MIDAS SHARE TIPS UPDATE: Wind is turning in Octopus...
- Hollywood silly money? I'd only have stuffed it under the...
- TONY HETHERINGTON: Boss behind firms fined £340k for more...
- CITY WHISPERS: Bill Ackman's cerulean eyes charm...
- Shipping broker Clarksons on list of shame after...
- Cost-of-living crunch wipes shine off Thomas Sabo jewellery
- Virgin Money's biggest independent investor...
- Britain's nascent battery industry receives shot in the...
- As world lurches from crisis to crisis, experts share...
- Where is Labour's 'white heat' revolution to revive...
- North Sea projects worth £21bn put at risk by Labour: Tax...
- British businesses awash with 'accidental' bosses who...
- 86-year-old Peter's woes with a faulty smart meter that...
- JOHCM UK EQUITY INCOME FUND: Rate cuts... and a spending...
- A good week - not before time, but let's not get carried...
- MIDAS SHARE TIPS: Why it soon won't be hip to give the...
- Helium and hydrogen company set to join stock market in...
- Ikea pushes back opening of its Oxford Street store to...